Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Can a galacto-oligosaccharide reduce the risk of traveller’s diarrhoea? A placebo-controlled, randomized, double-blind study

Hasle, Gunnar, Raastad, Ragnhild, Bjune, Gunnar, Jenum, Pål A., Heier, Lise · 2017 · Journal of Travel Medicine

Abstract

BACKGROUND: Diarrhoea is a common medical problem affecting travellers to Asia, Africa and Latin America. The use of prophylactic antimicrobial agents may increase the risk of contracting resistant bacteria. Findings indicate that oligosaccharides, i.e. carbohydrate chains of 3-10 monosaccharides, reduce the risk of diarrhoea. METHODS: We performed a placebo-controlled, double-blind study of a galacto-oligosaccharide, B-GOS (Bimuno®, Clasado Ltd, Milton Keynes UK), vs placebo for participants travelling to countries with a high/intermediate risk of diarrhoea for 7-15 days. The participants ingested 2.7g of B-GOS daily from 5 days prior to departure throughout the travel period, and returned a questionnaire, with a diarrhoea log, after their return. The case definition of diarrhoea was three or more loose stools per day. RESULTS: Of 523 enrolled subjects, 334 travellers managed to comply per protocol (PP), 349 followed the protocol at least until the onset of diarrhoea (conditionally evaluable, CE), and 408 followed the protocol with fewer than 5 days of deviance from the protocol (intention to treat, ITT). There was a significant reduction of diarrhoea incidence in the PP group (odds ratio = 0.56, P = 0.03), while the effect in the CE group was non-significant (OR = 0.65, P = 0.08). No significant effect was found during the first 7 days after starting with B-GOS, but from day 8 there was a significant effect in both the PP and CE groups (OR = 0.47, P = 0.02 and OR = 0.53, P = 0.03, respectively). The entire effect was seen in 1-day (i.e. self-limiting) diarrhoea (PP: OR = 0.25, P = 0.004). There was no effect on duration or the number of bowel movements during diarrhoea. The severity of diarrhoea was not affected. CONCLUSIONS: B-GOS reduces the risk of diarrhoea lasting 1 day. The protection seemed to start after a week of treatment with B-GOS. Strict compliance is crucial. The treatment is environmentally friendly and without adverse effects.

Overview

Integrity signals

Registry

Crossref · 10.1093/jtm/tax057

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 3

  1. 2000, Principels and Practice of Infectious Diseases, 2276
  2. 2000, Principels and Practice of Infectious Diseases, 2344
  3. 2000, Principels and Practice of Infectious Diseases, 2363

Cited by

See all 28

Metadata

Authors
Hasle, G., Raastad, R., Bjune, G., Jenum, P. A., & Heier, L.
Affiliations
University of Oslo (NO)
Corresponding author
Hasle, Gunnar
Venue
Journal of Travel Medicine
Published
2017-08-18
Volume
24
Issue
5
ISSN
  • 1195-1982 (ISSN-L)
  • 1708-8305
OpenAlex
W2758055522
Cited by
28
References
32
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 5 · 2018: 4 · 2017: 2
FWCI
3.08
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Travel Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Travel-related health issues
  • Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
galactooligosaccharides, traveler's diarrhea, prebiotics, diarrhea prevention, antimicrobial resistance, dietary supplementation, travel medicine, medication adherence, duration of protection, diarrhea severity
MeSH terms
Adult, Anti-Infective Agents, Diarrhea, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Oligosaccharides, Surveys and Questionnaires, Travel, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Can a galacto-oligosaccharide reduce the risk of traveller’s diarrhoea? A placebo-controlled, randomized, double-blind study. https://app.cochat.ai/papers/10.1093/jtm/tax057
The paper
Hasle, G., Raastad, R., Bjune, G., Jenum, P. A., & Heier, L. (2017). Can a galacto-oligosaccharide reduce the risk of traveller’s diarrhoea? A placebo-controlled, randomized, double-blind study. Journal of Travel Medicine. https://doi.org/10.1093/jtm/tax057

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.